Beijing Winsunny Pharmaceutical CO.LTD (601089) - Net Assets
Based on the latest financial reports, Beijing Winsunny Pharmaceutical CO.LTD (601089) has net assets worth CN¥3.59 Billion CNY (≈ $525.34 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.69 Billion ≈ $686.40 Million USD) and total liabilities (CN¥1.10 Billion ≈ $161.06 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Beijing Winsunny Pharmaceutical CO.LTD (601089) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.59 Billion |
| % of Total Assets | 76.54% |
| Annual Growth Rate | 37.06% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 65.63 |
Beijing Winsunny Pharmaceutical CO.LTD - Net Assets Trend (2020–2024)
This chart illustrates how Beijing Winsunny Pharmaceutical CO.LTD's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Beijing Winsunny Pharmaceutical CO.LTD for the complete picture of this company's asset base.
Annual Net Assets for Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)
The table below shows the annual net assets of Beijing Winsunny Pharmaceutical CO.LTD from 2020 to 2024. For live valuation and market cap data, see 601089 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.56 Billion ≈ $520.37 Million |
+2.29% |
| 2023-12-31 | CN¥3.48 Billion ≈ $508.73 Million |
+9.36% |
| 2022-12-31 | CN¥3.18 Billion ≈ $465.18 Million |
+161.57% |
| 2021-12-31 | CN¥1.22 Billion ≈ $177.84 Million |
+20.61% |
| 2020-12-31 | CN¥1.01 Billion ≈ $147.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Winsunny Pharmaceutical CO.LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 222.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.38 Billion | 38.80% |
| Other Components | CN¥2.17 Billion | 61.20% |
| Total Equity | CN¥3.54 Billion | 100.00% |
Beijing Winsunny Pharmaceutical CO.LTD Competitors by Market Cap
The table below lists competitors of Beijing Winsunny Pharmaceutical CO.LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Paramount Group Inc
NYSE:PGRE
|
$1.46 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
$1.47 Billion |
|
Daou Tech
KO:023590
|
$1.47 Billion |
|
Chengdu RML Technology Co. Ltd.
SHE:301050
|
$1.47 Billion |
|
Deutsche EuroShop AG
F:DEQ
|
$1.46 Billion |
|
Focus Technology Co Ltd
SHE:002315
|
$1.46 Billion |
|
Qingdao Yunlu Advanced Materials Technology Co. Ltd. A
SHG:688190
|
$1.46 Billion |
|
Med Life SA
RO:M
|
$1.46 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Winsunny Pharmaceutical CO.LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,468,416,437 to 3,544,556,038, a change of 76,139,601 (2.2%).
- Net income of 488,674,918 contributed positively to equity growth.
- Dividend payments of 236,592,213 reduced retained earnings.
- Other factors decreased equity by 175,943,104.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥488.67 Million | +13.79% |
| Dividends Paid | CN¥236.59 Million | -6.67% |
| Other Changes | CN¥-175.94 Million | -4.96% |
| Total Change | CN¥- | 2.20% |
Book Value vs Market Value Analysis
This analysis compares Beijing Winsunny Pharmaceutical CO.LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.47x to 2.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥2.79 | CN¥20.85 | x |
| 2021-12-31 | CN¥3.37 | CN¥20.85 | x |
| 2022-12-31 | CN¥6.61 | CN¥20.85 | x |
| 2023-12-31 | CN¥7.23 | CN¥20.85 | x |
| 2024-12-31 | CN¥7.38 | CN¥20.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Winsunny Pharmaceutical CO.LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.79%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.18%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.36x
- Recent ROE (13.79%) is below the historical average (18.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 26.13% | 10.36% | 1.48x | 1.71x | CN¥162.18 Million |
| 2021 | 25.96% | 11.08% | 1.32x | 1.78x | CN¥193.32 Million |
| 2022 | 13.83% | 13.55% | 0.75x | 1.36x | CN¥121.46 Million |
| 2023 | 14.09% | 14.64% | 0.73x | 1.31x | CN¥141.93 Million |
| 2024 | 13.79% | 14.18% | 0.72x | 1.36x | CN¥134.22 Million |
Industry Comparison
This section compares Beijing Winsunny Pharmaceutical CO.LTD's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,691,234,838
- Average return on equity (ROE) among peers: 6.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Winsunny Pharmaceutical CO.LTD (601089) | CN¥3.59 Billion | 26.13% | 0.31x | $1.46 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $903.62 Million | 4.28% | 2.45x | $1.16 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $441.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $5.01 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.80 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $3.04 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $9.03 Billion | 25.71% | 0.43x | $13.75 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $947.33 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $389.67 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.29 Billion | 2.31% | 2.07x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.32 Billion |
About Beijing Winsunny Pharmaceutical CO.LTD
Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical preparations and medical devices China and internationally. The company provides chemical drugs and traditional chinese medicines. Its products used in cardiovascular kind, chronic kidney disease, skin disease, digestive system, diabetes, neuropsychiatric system kind, mental nervous system… Read more